Literature DB >> 25817061

Clinical presentation in insulinoma predicts histopathological tumour characteristics.

Peter Wolf1, Yvonne Winhofer1, Sabina Smajis1, Christian-Heinz Anderwald1,2,3, Christian Scheuba4, Bruno Niederle4, Alois Gessl1, Anton Luger1, Michael Krebs1, Oskar Koperek5.   

Abstract

BACKGROUND: Insulinomas are rare neuroendocrine tumours (NETs) of the pancreas, characterized clinically by neuroglycopenic symptoms during periods of substrate deficiency. The gold standard test for diagnosing an insulinoma is a 72-h fast. However, the prognostic value of parameters in the standardized 72-h fast on histopathological tumour criteria and clinical presentation has not been examined.
METHODS: In thirty-three patients diagnosed with an insulinoma records, and data were investigated retrospectively. Histopathological tumour characteristics, including staging, grading and size, were reviewed. Grading was performed using Ki-67 index. Cut-off values for classical grading (G(clas)) were set at G1(clas) ≤ 2%, G2(clas) 3-20% &amp; G3(clas) >20% and for modified grading (G(mod)) at G1(mod) <5%, G2(mod) 5-20% &amp; G3(mod) >20%.
RESULTS: When G(mod) criteria were applied, the initial blood glucose was lower in GII/III(mod) patients compared to GI(mod) (2.8 ± 0.8 vs 3.8 ± 1.3 mmol/l; P = 0.046). Basal and end of fast levels of insulin (basal insulin 71 ± 61 vs 20 ± 16 mU/l; P < 0.001; end of fast insulin 77 ± 51 vs 21 ± 20 mU/l; P < 0.001) and c-peptide (basal c-peptide 5.4 ± 2.4 vs 2.7 ± 1.6 μg/l; P = 0.004; end of fast c-peptide 5.3 ± 2.4 vs 2.5 ± 1.4 μg/l; P = 0.001) were significantly higher in GII/III(mod) than in GI(mod). No differences between the groups were observed when G(clas) criteria were applied. Additionally, close correlations were observed between insulin concentration, Ki-67 index and tumour size.
CONCLUSION: This study shows an impact of histopathological tumour characteristics in patients suffering from an insulinoma on clinical presentation during a standardized 72-h fast. Lower initial blood glucose levels and higher concentrations of insulin and c-peptide are associated with worse tumour grading and larger tumour size.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25817061     DOI: 10.1111/cen.12777

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Early detection of cognitive impairment in patients with insulinoma.

Authors:  Hongmei Dai; Hao Chen; Xiafei Hong; Xianlin Han; Qiang Xu; Haiyu Pang; Jing Yuan; Xianze Wang; Peiran Xu; Jialin Jiang; Rui Jiang; Zhe Zhuang; Yupei Zhao; Wenming Wu
Journal:  Endocrine       Date:  2019-07-10       Impact factor: 3.633

Review 2.  Malignant insulinoma: Can we predict the long-term outcomes?

Authors:  Maja Cigrovski Berkovic; Monika Ulamec; Sonja Marinovic; Ivan Balen; Anna Mrzljak
Journal:  World J Clin Cases       Date:  2022-06-06       Impact factor: 1.534

3.  Hypoglycemia in a Patient With a Polyhormonal Pancreatic Neuroendocrine Tumor With Evidence of Endocrine Progenitors.

Authors:  Zachary B Simons; Rachel C Morgan; Laurel Rose; Jennifer B Nelson; Sarah A Tersey; Raghavendra G Mirmira
Journal:  J Endocr Soc       Date:  2018-01-16

Review 4.  Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Authors:  Bryan Oronsky; Patrick C Ma; Daniel Morgensztern; Corey A Carter
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

5.  Metastatic Insulinoma Presenting With Postprandial Hypoglycemia.

Authors:  Monique Debrah Maher; Dimpi Nitin Desai; Mandeep Bajaj
Journal:  AACE Clin Case Rep       Date:  2022-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.